Firebrick Pharma Limited (AU:FRE)
ASX:FRE
FRE Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.09
Previous CloseN/A
Volume87.61K
Average Volume (3M)91.61K
Market Cap
AU$15.91M
Enterprise ValueAU$13.71M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-1.69
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,479,080
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetZero reported debt provides durable financial flexibility versus peers, lowering refinancing and insolvency risk. For a cash-burning biotech, no leverage reduces fixed obligations and gives management time to pursue regulatory or commercial milestones without immediate debt pressures.
Product-Level Gross MarginA positive gross margin indicates the lead product can cover direct costs and suggests unit economics that can scale. If commercial uptake improves, margins offer a pathway to operating leverage and eventual profitability even if current operating costs keep overall results negative.
Focused Anti-Infectives NicheConcentrated focus on hospital anti-infectives targets a structural, regulated demand stream where infection-prevention products can secure steady institutional contracts. Clinical/regulatory barriers can also create competitive moats for approved niche therapeutics over time.
Bears Say
Sharp Revenue DeclineA ~74% revenue drop signals fragile commercial traction and high volatility in sales execution or market access. Such material declines undermine forecasts, reduce operating leverage, and make multi-quarter planning difficult absent new durable revenue channels or successful market rollouts.
Persistent Large LossesExtremely negative margins reflect that operating costs far exceed sales and that current scale is insufficient. Persistent large losses erode equity, risk dilution from future financings, and constrain the firm's ability to invest in commercialization or R&D without external funding.
Negative Cash Generation / BurnConsistent negative operating and free cash flow mean the business is not self-funding and requires external capital to sustain operations. Even with reduced burn versus prior years, ongoing outflows present financing risk and limit strategic options over the medium term.
Firebrick Pharma Limited News
FRE FAQ
What was Firebrick Pharma Limited’s price range in the past 12 months?
Firebrick Pharma Limited lowest share price was AU$0.05 and its highest was AU$0.09 in the past 12 months.
What is Firebrick Pharma Limited’s market cap?
Firebrick Pharma Limited’s market cap is AU$15.91M.
When is Firebrick Pharma Limited’s upcoming earnings report date?
Firebrick Pharma Limited’s upcoming earnings report date is Aug 27, 2026 which is in 147 days.
How were Firebrick Pharma Limited’s earnings last quarter?
Firebrick Pharma Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Firebrick Pharma Limited overvalued?
According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued.
Does Firebrick Pharma Limited pay dividends?
Firebrick Pharma Limited does not currently pay dividends.
What is Firebrick Pharma Limited’s EPS estimate?
Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Firebrick Pharma Limited have?
Firebrick Pharma Limited has 252,479,080 shares outstanding.
What happened to Firebrick Pharma Limited’s price movement after its last earnings report?
Firebrick Pharma Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Firebrick Pharma Limited?
Currently, no hedge funds are holding shares in AU:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Firebrick Pharma Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:FRE Sentiment 90%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.66%
12-Months-Change
Fundamentals
Return on Equity
-140.26%
Trailing 12-Months
Asset Growth
24.27%
Trailing 12-Months
Company Description
Firebrick Pharma Limited
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Technical Analysis
Hexima Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Inoviq Ltd
―